HUNTSVILLE, Ala. — Qualitest Pharmaceuticals has received approval from the Food and Drug Administration for its Emoquette oral contraceptive.
The company, acquired late last year by Endo Pharmaceuticals, said Friday that it was cleared by the FDA to market Emoquette (desogestrel and ethinyl estradiol) in 0.15 mg/0.03 mg tablets.
The product is a generic version of Ortho-McNeil Pharmaceuticals’ Ortho-Cept contraceptive.
A combination hormone medication, ethinyl estradiol and desogestrel are designed prevent ovulation. The birth control therapy also causes changes in the cervical mucus and uterine lining, making it more difficult for sperm to reach the uterus and for a fertilized egg to attach to the uterus.
